Kolexia
Taksin-Bressot Anne-Laure Hématologie
Taksin-Bressot Anne-Laure
Hématologie
Centre hospitalier de Versailles
Le Chesnay, France
62 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Syndromes myélodysplasiques Entorses et foulures Délétion de segment de chromosome Préleucémie Cardiotoxicité Aberrations des chromosomes

Collaborateurs

Voir plus
Merabet Fatiha
Merabet Fatiha
Centre hospitalier de Versailles, Le Chesnay, France
Besson Caroline
Besson Caroline
Centre hospitalier de Versailles, Le Chesnay, France
Rousselot Philippe
Rousselot Philippe
Hôpital Saint-Louis, Paris, France
Farhat Hassan Yann
Farhat Hassan Yann
Centre hospitalier de Versailles, Le Chesnay, France

Industries

Voir plus
A+A
12 collaboration(s)
Dernière en 2020
Amgen
9 collaboration(s)
Dernière en 2023
BMS
7 collaboration(s)
Dernière en 2023
Janssen
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome: A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Essai Clinique (Groupe Français des Myélodysplasies)   02 janvier 2023
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome: A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Essai Clinique (Groupe Français des Myélodysplasies)   02 janvier 2023
CPX-351 TA-SMP: A Phase II Study of CPX-351 Monotherapy in Acute Myeloid Leukemia
Essai Clinique (French Innovative Leukemia Organisation)   17 octobre 2022
Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS
Blood   05 novembre 2020
Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity.
European heart journal. Cardiovascular Imaging   08 janvier 2018
Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
Leukemia & lymphoma   28 novembre 2017
Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity.
Annales de cardiologie et d'angeiologie   29 mars 2017
French Registry of First-line Treatment of Acute Promyelocytic Leukemia: The French Registry on the First-line Treatment of Non High-risk Acute Promyelocytic Leukemia (APL) in Patients Aged ≤ 70 Years
Essai Clinique (Teva)   17 octobre 2016
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
Leukemia   26 octobre 2015
Azacitidine for the treatment of relapsed and refractory AML in older patients.
Leukemia research   24 novembre 2014